List view / Grid view
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
2 August 2024 | By Eurofins Discovery
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
The new study demonstrated that a small molecule inhibitor, BLZ945, could be used as a potential therapeutic to achieve viral clearance.
In this Q&A, we had the privilege of speaking to COUR Pharmaceuticals’ CEO John Puisis. He offers insights into how their innovative immune-modifying nanoparticle platform differs from traditional approaches for treating immune-mediated diseases.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
A new study shows that changes in clonal dominance characterises T-cell memory against multiple COVID-19 variants following mRNA vaccinations.
A recent study has highlighted the impact of endotoxins on the accuracy of three-dimensional (3D) cancer models. In this Q&A, Dr Bjorn Vergauwen reveals details and key findings of the research.
Understanding heart changes at the molecular level during early infection with adenovirus could enable identification of those at higher risk of arrhythmia.
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted…
Single-cell RNA analysis provides an immunological explanation for the association between periodontitis and diabetes mellitus.
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
